Haemonetics Co. (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Haemonetics Co. (NYSE:HAE) has earned a consensus rating of “Moderate Buy” from the four brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $109.50.

A number of equities analysts have issued reports on HAE shares. Needham & Company LLC upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective on the stock in a research report on Wednesday, June 12th. JMP Securities boosted their price objective on shares of Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. Finally, Barrington Research boosted their price objective on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research report on Friday, May 10th.

Insider Activity

In other news, EVP Anila Lingamneni sold 2,305 shares of Haemonetics stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $95.00, for a total transaction of $218,975.00. Following the sale, the executive vice president now owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Haemonetics news, EVP Michelle L. Basil sold 12,990 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $88.08, for a total value of $1,144,159.20. Following the sale, the executive vice president now owns 31,257 shares in the company, valued at $2,753,116.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Anila Lingamneni sold 2,305 shares of the company’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total transaction of $218,975.00. Following the completion of the sale, the executive vice president now owns 12,295 shares in the company, valued at approximately $1,168,025. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,516 shares of company stock valued at $2,638,056. Corporate insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds and other institutional investors have recently bought and sold shares of HAE. SG Americas Securities LLC purchased a new stake in Haemonetics in the fourth quarter worth about $345,000. Pacer Advisors Inc. grew its holdings in shares of Haemonetics by 64.8% during the fourth quarter. Pacer Advisors Inc. now owns 9,098 shares of the medical instruments supplier’s stock valued at $778,000 after buying an additional 3,579 shares during the last quarter. LVZ Inc. grew its holdings in shares of Haemonetics by 9.4% during the fourth quarter. LVZ Inc. now owns 3,006 shares of the medical instruments supplier’s stock valued at $257,000 after buying an additional 259 shares during the last quarter. ABLE Financial Group LLC grew its holdings in shares of Haemonetics by 28.4% during the fourth quarter. ABLE Financial Group LLC now owns 7,251 shares of the medical instruments supplier’s stock valued at $620,000 after buying an additional 1,606 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Haemonetics by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,874 shares of the medical instruments supplier’s stock valued at $1,956,000 after buying an additional 838 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $91.06 on Wednesday. The stock has a market cap of $4.64 billion, a PE ratio of 39.76, a PEG ratio of 1.66 and a beta of 0.29. The company’s fifty day moving average is $87.07 and its 200 day moving average is $83.95. Haemonetics has a 52 week low of $70.74 and a 52 week high of $97.97. The company has a quick ratio of 1.50, a current ratio of 2.56 and a debt-to-equity ratio of 0.83.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to analysts’ expectations of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The firm’s revenue was up 12.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 EPS. Research analysts anticipate that Haemonetics will post 4.57 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.